日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Structural optimization of drug molecules with incrementally trained language models

利用增量训练的语言模型进行药物分子结构优化

Hörmann, Tim; Mayer, Domenic; Lewandowski, Max; Hunklinger, Andrea; Wein, Thomas; Merk, Daniel

A Nurr1 Agonist Derived from the Natural Ligand DHI Induces Neuroprotective Gene Expression.

源自天然配体DHI的Nurr1激动剂可诱导神经保护基因表达

Egner Markus, Busch Romy, López-García Úrsula, Lewandowski Max, Höfner Georg, Wein Thomas, Marschner Julian A, Merk Daniel

Structural and mechanistic profiling of Nurr1 modulation by vidofludimus enables structure-guided ligand design

通过对维多氟替卡松调控Nurr1的结构和机制进行分析,可以实现结构导向的配体设计。

López-García, Úrsula; Vietor, Jan; Marschner, Julian A; Heering, Jan; Morozov, Vasily; Wein, Thomas; Merk, Daniel

Lead Structure-Based Hybridization Strategy Reveals Major Potency Enhancement of SirReal-Type Sirt2 Inhibitors

基于先导化合物结构的杂交策略揭示了SirReal型Sirt2抑制剂效力的显著提升

Frei, Matthias; Wirawan, Ricky; Wein, Thomas; Bracher, Franz

Balsalazide-Derived Heterotriaryls as Sirtuin 5 Inhibitors: A Case Study of a Reversible Covalent Inhibition Strategy

巴柳氮衍生的杂三芳基化合物作为Sirtuin 5抑制剂:可逆共价抑制策略案例研究

Wirawan, Ricky; Huber, Simon A; Wein, Thomas; Bracher, Franz

Lead-Structure-Based Rigidization Approach to Optimize SirReal-Type Sirt2 Inhibitors.

基于先导化合物结构的刚性化方法优化 SirReal 型 Sirt2 抑制剂

Frei Matthias, Wein Thomas, Bracher Franz

Tailored SirReal-type inhibitors enhance SIRT2 inhibition through ligand stabilization and disruption of NAD(+) co-factor binding.

定制的 SirReal 型抑制剂通过配体稳定和破坏 NAD(+) 辅因子结合来增强 SIRT2 抑制作用

Wirawan Ricky, Frei Matthias, Heider Anna, Papenkordt Niklas, Friedrich Florian, Wein Thomas, Jung Manfred, Groll Michael, Huber Eva M, Bracher Franz

Biceps Femoris Injury a Rarity: A Case Report

股二头肌损伤罕见:病例报告

Strasser, Roland; Wein, Thomas; Wieder, Marc; Erhardt, Johannes; Kaufmann, Jörg